Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ryoichi Unno is active.

Publication


Featured researches published by Ryoichi Unno.


Tetrahedron | 1995

SYNTHESIS AND BIOLOGICAL EVALUATION OF BOTH ENANTIOMERS OF DYNEMICIN A MODEL COMPOUND

Toshio Nishikawa; Maki Yoshikai; Kazuyo Obi; Takatoshi Kawai; Ryoichi Unno; Takahito Jomori; Minoru Isobe

Abstract A novel 1,4-asymmetric induction was developed for the synthesis of chiral dynemicin A model compound. By using this reaction, both enantiomers were synthesized from chiral alcohol prepared by lipase catalyzed resolution. The biological activities of these compounds were examined.


Bioorganic & Medicinal Chemistry | 1997

Structure-activity relationships of cyclic enediynes related to dynemicin A. I. Synthesis and antitumor activity of 9-acetoxy enediynes equipped with aryl carbamate moieties.

Ryoichi Unno; Hisashi Michishita; Hideaki Inagaki; Yoko Suzuki; Yutaka Baba; Takahito Jomori; Toshio Nishikawa; Minoru Isobe

A series of the 9-acetoxy enediyne compounds, 6a-k which were simplified from natural dynemicin A, and designed to be equipped with various aryl carbamate moieties, was synthesized and evaluated for DNA-cleaving ability, in vitro cytotoxicity, and in vivo antitumor activity. As a result of this study of the structure-activity relationships (SAR) with regard to the Rt substituent, both compounds 6a and 6f with the phenyl carbamate and 4-chlorophenyl carbamate moiety, respectively, were found to exhibit significant activity (T/C > 200%) against murine P388 leukemia in mice, in spite of having IC50 values in the micromolar range. In particular, compound 6f showed the most potent activity with a maximum T/C of 256% at a daily dosage of 4.0 mg/kg for four days. Furthermore, both compounds 6a and 6f were effective against Meth A sarcoma in mice and inhibited 71 and 77% of the tumor growth at 2.0 and 3.0 mg/kg dosages, respectively. In contrast to 6f, compound 6i possessing the 2-nitrophenyl carbamate moiety showed only a slight in vivo activity, while it had about one order of magnitude higher in vitro cytotoxicity than 6f. For the stereochemistry-activity relationships at the C9 position, the (9R*)-isomers of 6c, 6g, and 6j were found to show higher in vitro and in vivo potencies than the corresponding (9S*)-isomers.


Bioorganic & Medicinal Chemistry | 1997

Synthesis and antitumor activity of water-soluble enediyne compounds related to dynemicin a

Ryoichi Unno; Hisashi Michishita; Hideaki Inagaki; Yoko Suzuki; Yutaka Baba; Takahito Jomori; Toshio Nishikawa; Minoru Isobe

The enediyne compounds 9-14, simple dynemicin A (1) analogues equipped with aryl carbamate moieties with various aliphatic amino or hydroxy groups at the C9 position, were synthesized and evaluated for DNA-cleaving ability, in vitro cytotoxicity, and in vivo antitumor activity. We found that the water-soluble compounds, in which the tert-amines such as the 2-(dimethylamino)ethyl (10b, 14b), 2-(pyrrolidino)ethyl (10c), or 1-azabicyclo[3.3.0]oct-5-ylmethyl (10d, 12d, 14d) group were attached, showed not only the enhanced in vivo antitumor activity but also the decreased toxicity compared to the corresponding 9-acetoxy enediyne compounds 6-8. In particular, compound 10c showed the most enhanced in vivo antitumor activity (T/C = 222% at a daily dose of 1.25 mg/kg for 4 days) at about half of the dose of 6. These results suggest that both the enhanced antitumor activity and the reduced toxicity might be due to the improved bioavailability or disposition of compounds 6-8 by their water-solubilization.


Archive | 1987

Hydantoin derivatives for treating complications of diabetes

Masayasu Kurono; Yasuaki Kondo; Takuji Yamaguchi; Kenji Miura; Toshinao Usui; Naofumi Terada; Kyoichi Asano; Kuniharu Mizuno; Akira Matsubara; Noriaki Kato; Kiichi Sawai; Ryoichi Unno; Hiroshi C O Sanwa Kagaku Ozawa; Masato Fukushima


Archive | 1987

Glycyrrhetic acid derivatives and use thereof

Masayasu Kurono; Ryoichi Unno; Hiromoto Kimura; Mitsuro Sanwa Kagaku Kenkyusho Co. Ltd. Oka; Keiko Sanwa Kagaku Kenkyusho Co. Ltd. Hasegawa; Shinichi Ikeda; Noboru Kuboyama; Takashi Ito; Kiichi Sawai; Shunsuke Ito


Tetrahedron Letters | 1978

Petasinine and petasinoside, two minor alkaloids possessing a new necine isolated from petasites japonicus maxim.

Kiyoyuki Yamada; Hiroshi Tatematsu; Ryoichi Unno; Yoshimasa Hirata; Iwao Hirono


Chemical & Pharmaceutical Bulletin | 1994

Synthesis and aldose reductase inhibitory activity of 2-substituted 6-fluoro-2,3-dihydrospiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-diones

Ryoichi Unno; Takuji Yamaguchi; Toshinao Usui; Takuji Kakigami; Masato Fukushima; Kuniharu Mizuno; Yutaka Baba; Masayasu Kurono


Chemical & Pharmaceutical Bulletin | 1997

Synthesis and biological evaluation of novel cyclic enediyne compounds related to dynemicin A as antitumor agents.

Ryoichi Unno; Hisashi Michishita; Hideaki Inagaki; Yutaka Baba; Takahito Jomori; Toshio Nishikawa; Minoru Isobe


Archive | 1992

Glycyrrhetinic acid derivatives

Masayasu Kurono; Yoshiro Ishiwata; Syoji Yokochi; Kyoichi Asano; Takahiko Mitani; Takuji Kakigami; Noriyuki Iwata; Kougaku Isogawa; Yutaka Baba; Hiroyuki Ohwaki; Kiichi Sawai; Hiromoto Kimura; Masato Fukushima; Ryoichi Unno; Tamaki Ohtuka


Archive | 1990

HYDANTOIN DERIVATIVES FOR TREATING COMPLICATIONS OF DIABETES AND CIRCULATORY DISEASES

Masayasu Kurono; Ryoichi Unno; Hiromoto Kimura; Noboru Tomiya; Kiichi Sawai; Kenji Miura; Toshinao Usui; Yasuaki Kondo; Yukiya Tanaka; Shigeyoshi Nakamura; Tsunemasa Suzuki; Motohide Hayashi

Collaboration


Dive into the Ryoichi Unno's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mitsuru Oka

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Takuji Kakigami

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge